Analysis of Staged Features of Gastritis-Cancer Transformation and Identification of Potential Biomarkers in Gastric Cancer
Ruikang Jia,Xiaohui Guo,Huiyun Liu,Feiyue Zhao,Zhibin Fan,Menglei Wang,Jianliang Sui,Binghua Yin,Zhihong Wang,Zhen Wang
DOI: https://doi.org/10.2147/JIR.S390448
IF: 4.5
2022-12-28
Journal of Inflammation Research
Abstract:Ruikang Jia, 1, 2, &ast Xiaohui Guo, 3, &ast Huiyun Liu, 2 Feiyue Zhao, 2 Zhibin Fan, 2 Menglei Wang, 2 Jianliang Sui, 1, 2 Binghua Yin, 3 Zhihong Wang, 4 Zhen Wang 1, 5 1 The Affiliated Hospital and the Medical College, Hebei University of Engineering, Handan, Hebei Province, People's Republic of China; 2 Key Laboratory of Chinese Medicine for Gastric Medicine, Hebei Province, Handan Pharmaceutical Co. LTD, Handan, People's Republic of China; 3 Handan Central Hospital, Handan, Hebei Province, People's Republic of China; 4 People's Hospital of Huangzhou District, Huanggang City, People's Republic of China; 5 Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, and Department of Biochemistry and Molecular Biology, Fudan University Shanghai Medical College, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhen Wang, The Affiliated Hospital and the Medical College, Hebei University of Engineering, Handan, Hebei Province, People's Republic of China, Tel +8619903200632, Email Purpose: This work aims to elucidate the staged characteristics during gastritis-cancer transformation based on the transcriptome and use bioinformatics to identify potential biomarkers. Patients and Methods: We collected blood samples from healthy controls, patients with non-atrophic gastritis, atrophic gastritis, and gastric cancer, and tissue samples from patients with gastric cancer, respectively. RNA-seq was then performed. Differentially expressed genes, weighted gene co-expression network analysis and functional enrichment analysis were used to illustrate the staged characteristics of gastritis-cancer transformation. Genes with diagnostic potential were further identified in combination with ROC analysis. Additionally, for the gastric cancer stage, the gene expression of the collected tissue transcriptome was validated using the Cancer Genome Atlas and combined with survival analysis to identify potential biomarkers. Results: The 279 overlapping genes among the differentially expressed genes of NAG, AG and CA indicated that the expression characteristics of different stages were different. However, the 2243 overlapping genes of differential genes between adjacent stages indicated a certain consistency in the expression characteristics of stage development. The core functions of different stages have strong stage specificity and basically have no similarities. Twenty genes with diagnostic potential for AG or CA were obtained, respectively, and no gene could effectively differentiate NAG samples. Thirty-four potential biomarkers for gastric cancer were identified, of which 14 genes have not been reported, including ACTG2, C1QTNF2, NCAPH and SORCS1. Conclusion: There may be a stable development mechanism in the process of gastritis-carcinoma transformation, resulting in the differences in the performance of each stage. The newly discovered staging features and potential biomarkers in this work can provide references for related research. Keywords: gastritis-cancer transformation, transcriptome, bioinformatics, biomarker Chronic inflammatory disease has been considered as an important cause of death in the world today, and its long-term existence is inseparable from the occurrence and development of cancer. 1–3 According to pathological and epidemiological studies, the gastritis-cancer transformation is divided into the following successive stages: chronic non-atrophic gastritis (CNAG), chronic atrophic gastritis (CAG) with or without intestinal metaplasia (IM) and dysplasia. 4 CAG, a stage before gastric cancer, carries the risk of developing gastric cancer (GC) if left uncontrolled. 5 Currently, endoscopy and histopathological biopsy are mainly used for the clinical diagnosis of atrophic gastritis (AG) and GC, which is an invasive diagnostic method, and the main treatment methods for gastric cancer include surgery, chemotherapy, radiotherapy and targeted therapy. 6,7 Early detection of GC risk groups is critical for improving the survival rate of GC, and to address the large at-risk population, non-invasive tests have been used to predict precancerous conditions to minimize the need for invasive testing. 8 Pepsinogen, pepsinogen I/II ratio, and gastrin serum levels have been used to screen high-risk subjects for gastric precancerous lesions, and a meta-analysis showed their diagnostic value. 9 Compared with traditional GC biomarkers such as CEA, CA19-9 and CA72-4, the biomarker panel composed of P -Abstract Truncated-
immunology